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Abstract 
Tuberculosis remains the leading cause of preventable deaths worldwide and 
unsuccessful therapy is mainly due to non-compliance with very prolonged treatments, 
often associated with severe side-effects. Overcoming this problem demands the 
introduction of drug carriers releasing the antimicrobial agents in a targeted and 
sustained manner, allowing reduction in frequency and dosing numbers. Nano and 
microparticles have taken the forefront of this approach, providing the means for the 
desired improvement of therapeutic schedules. Natural polymers are strong candidates 
as matrix forming materials, usually exhibiting biocompatibility, biodegradability, low 
cost and some technological advantages as compared with synthetic counterparts. In this 
review, natural particulate carriers developed for tuberculosis therapy are presented, 
mainly focusing on the use of polysaccharides and lipids. Their effectiveness is 
discussed taking into account their composition. Finally, considerations on the general 
potential of natural materials for this application, as well as key factors still to be 
addressed, are discussed. 
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Introduction 
Tuberculosis is a highly contagious bacterial infection caused by Mycobacterium 
tuberculosis and, although its first reliable therapeutic approach came out in 1944, with 
the discovery of streptomycin, the disease remains the leading cause of preventable 
deaths worldwide (Ranjita et al., 2011). 86% of the cases are reported to occur both in 
Asia and Africa, especially in developing countries that lack adequate health conditions 
and face difficult medical access. Moreover, some disease conditions are known to 
increase the susceptibility of tuberculosis infection, such as the infection with human 
immunodeficiency virus (HIV), diabetes and chronic lung disease (Ranjita et al., 2011, 
Doherty and Andersen, 2005). In this manner, the disease is a major burden in 
developing countries, but it also remains present in many developed countries. Humans 
are the primary host of Mycobacterium tuberculosis, which is disseminated via 
inhalation of bacteria-containing droplets. For this reason, the disease is known to 
mainly affect the lungs (Blasi et al., 2009). However, it can also disseminate to 
extrapulmonary regions, affecting any other place in the organism, mainly the central 
nervous and the circulatory systems (Ranjita et al., 2011, Sosnik et al., 2010). When the 
infectious droplet nuclei are inhaled, mycobacteria reach the alveoli and accumulate 
inside alveolar macrophages. Once inside macrophages, a cascade of events is started. 
As a result, the infection can be contained or the bacillus can keep multiplying, leading 
to the progression to active disease (Blasi et al., 2009, du Toit et al., 2006). This 
difference in responses mainly depends on whether the infected individual has the 
ability to start an adequate immunological response. Further details on the pathogenesis 
of tuberculosis might be found in (Russell, 2007, Hunter, 2011). When capturing 
bacteria, as occurs for any other particulate matter, macrophages become activated. This 
activation refers to a state of enhanced cellular metabolism, mobility, lysosomal enzyme 
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activity and cytocidal capacity (Lewis and McGee, 1992, Ahsan et al., 2002). Activation 
mainly occurs in response to activation signals such as interferon-α, along with the 
exposure to a microbial product like lipopolysaccharide (Mosser, 2003). Generally, 
activated macrophages are not more phagocytic than others, but they possess a 
markedly enhanced ability to eliminate intracellular microorganisms (Mosser, 2003, 
Lewis and McGee, 1992). Yet, a recent work reports the increase of phagocytic activity 
by mycobacteria-infected macrophages as compared with non-infected cells (Hirota et 
al., 2008). In the particular case of tuberculosis, starting this activation process initiates 
a pro-inflammatory cascade that includes the recruitment of several other types of cells 
to the infection site. This contributes to the formation of the granuloma, which consists 
of a core of infected macrophages surrounded by mononuclear phagocytes, capillaries 
and a peripheral layer of lymphocytes (Blasi et al., 2009, Misra et al., 2011). The 
formation of the granuloma endows the bacteria with the ability to avoid cell mediated 
immune response (Armstead and Li, 2011).  
Current tuberculosis therapy is complex and involves the so-called ‘directly observed 
treatment, short-course’ (DOTS), which uses a multidrug approach to prevent drug 
resistance. The treatment demands the oral administration of four different antibiotics 
for a period of six months and is many times associated with severe side effects, such as 
hepatotoxicity, nephrotoxicity and ototoxicity (Sosnik et al., 2010, Smola et al., 2008). 
This conjugation of a prolonged treatment and the recurrent appearance of side effects, 
results frequently in very low patient compliance, leading to a relapse of symptoms and 
increased prevalence of multidrug-resistant strains (Pandey and Khuller, 2005a). Having 
this problem identified, industrial and academic researchers are directing efforts to the 
development of alternatives that simultaneously increase patient compliance and 
provide therapeutic efficacy. On one side, research is being directed towards the 
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development of new and potent drugs that overcome resistance mechanisms developed 
by bacteria, although these will take years to reach the market. On the other side, the use 
of alternative routes of administration and new formulations of anti-tubercular drugs 
that provide sustained release is being explored.  
This latter approach is the focus of the present review. Herein, several alternatives 
proposed in the literature for the administration of anti-tubercular drugs are presented, 
considering not only unconventional administration routes, but also the use of 
specifically designed drug delivery carriers. These approaches envisage the 
improvement of patient compliance, with consequent enhanced therapeutic results, not 
only because they possibly reduce doses and dosing frequency but also because this will 
inevitably lead to reduced incidence of side effects. A significant part of the works 
available in the field propose drug carriers based on synthetic polymers, namely 
polylactic acid (PLA) and polylactic-co-glycolic acid (PLGA), which are known for 
their biocompatibility. However, these synthetic carriers present some critical 
limitations, mainly related with low drug encapsulation, the elimination of residual 
organic solvents and generally associated high costs. These problems potentiate the 
choice for natural materials, which have the great advantage of being more prone to 
biodegradability and biocompatibility, and are readily available at low and convenient 
prices (Beneke et al., 2009). This review will be dedicated to multiparticulate drug 
delivery systems whose composition is based on natural materials, emphasising the 
application of polysaccharides and lipids in the production of micro and nanocarriers. 
Liposomal formulations are also relevant in this field, but a very recent and complete 
review on the subject is available (Pinheiro et al., 2011) and, therefore, the application 
of these systems will not be included. The effectiveness of formulations will be 
addressed on the basis of their specific composition and intrinsic properties. In addition, 
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a general consideration on the potential of carriers formed by natural materials for a 
particular application in the design of anti-tubercular drug delivery systems will be 
drawn by the authors.  
 
Natural drug carriers designed for tuberculosis treatment  
So far, tuberculosis therapies have mainly explored conventional routes of 
administration, such as oral and intra-muscular, as well as the most usual 
pharmaceutical dosage forms, which include tablets, capsules and injectable solutions 
(Blasi et al., 2009). The oral route, currently the most used in anti-tubercular therapy, 
although very convenient for the patients, presents limitations related with premature 
drug degradation and difficulty to allow the drug to reach relevant tissues, such as the 
lungs. Besides, many antibiotics that are highly active in vitro are often inactive against 
intracellular bacteria, due to their poor penetration into the cells (Saraogi et al., 2011). 
Therefore, it has been recognised that the necessary decrease of dosing frequency, as 
well as that of side-effects, cannot be accomplished by conventional therapeutic 
approaches, instead demanding the use of drug delivery systems that provide controlled 
release and concentrate the drug at the infection site. For instance, as 80% of 
tuberculosis cases affect the lungs, which is the site of entrance of the bacteria, the 
direct targeting of alveolar macrophages, where bacteria are hosted, would be extremely 
useful. This effect could be achieved through inhalable therapies that provide high local 
concentration of drug and rapid onset of killing action (Mitchison and Fourie, 2010). In 
this manner, the encapsulation of drugs into micron- or nanosized carriers might be the 
adequate strategy to both decrease toxicity and provide a controlled release (Blasi et al., 
2009, Sosnik et al., 2010). As an additional advantage, it is known that particulate 
matter has increased macrophage capture as compared with solutes, owing to 
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phagocytosis (Ahsan et al., 2002, Geiser, 2010, Misra et al., 2011). Moreover, as it was 
previously emphasised, there is an indication of increased phagocytic activity evidenced 
by mycobacterium-infected macrophages (Hirota et al., 2008). Both nanoparticles and 
microparticles have, thus, been proposed to this end, either being composed of natural 
or synthetic materials. In this context, the greatest advantages achieved by natural 
polymeric particles, as compared to synthetic counterparts, are the highest encapsulation 
efficiency and the lower drug-to-polymer ratio, allowing improved loadings with 
smaller polymer quantities (Blasi et al., 2009, Pandey and Ahmad, 2011). Natural 
polymers evidence some specific advantages, including their general biocompatibility, 
low cost and hydrophilicity (Liu et al., 2008, Anwunobi and Emeje, 2011, Mizrahy and 
Peer, 2012). The latter is of particular importance in designing drug delivery systems, as 
it permits avoiding the use of organic solvents. Table 1 presents the advantages and 
limitations of natural polymers as matrix forming materials. In the next sections, an 
overview of the potentialities of those carriers that are based on natural materials, which 
include several polysaccharides and lipids, is provided. Tables 2 and 3 present a 
summary of the most important findings of the works described along this review. 
Table 3 specifically addresses the results obtained in in vivo studies performed in 
animal models of tuberculosis, providing data on the therapeutic efficacy of the 
developed systems. 
 
Polymeric microparticles 
A very short list of natural materials was used so far to produce microparticles aimed at 
delivering anti-tubercular drugs. Alginate, chitosan, hyaluronic acid, carboxymethyl 
cellulose and gelatin are those reported in the literature, addressing both oral and 
pulmonary administration. The chemical structures of these materials are depicted in 
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Figure 1. Alginate is a polysaccharide composed of β-D-mannuronic and α-L-guluronic 
acid that is usually extracted from brown seaweed. Chitosan is another polysaccharide, 
is composed of D-glucosamine and N-acetyl-glucosamine units, and is obtained by the 
deacetylation of chitin, which is extracted from arthropods, mainly crab shells. 
Hyaluronic acid is a glycosaminoglycan composed of units of N-acetyl-glucosamine 
and glucuronic acid. Carboxymethylcellulose is a cellulose derivative in which the 
glucopyranose backbone presents carboxymethyl groups attached to some of its 
hydroxyl moieties. The application of these polymers in drug delivery is widely 
reported, as they evidence biocompatibility, biodegradability and, in some cases, 
mucoadhesive properties, which are more pronounced in chitosan (Beneke et al., 2009, 
Chiellini et al., 2008, Sudhakar et al., 2006). Gelatin is a protein derived from collagen, 
with reported biocompatibility and biodegradability (Chiellini et al., 2008, Malafaya et 
al., 2007). Albumin microspheres are also described (Yeboah and D'souza, 2009), but 
their application focuses on the oral administration of vaccines, therefore being out of 
the scope of this review.  
To the best of our knowledge, the first report on the production of natural microparticles 
for the delivery of anti-tubercular drugs appeared in 2003, using alginate as matrix-
forming material and focusing on oral administration. The microparticles (100 µm) 
were prepared by ionic gelation with Ca
2+
 and encapsulated isoniazid, rifampicin and 
pyrazinamide in combination. Upon oral administration of a single dose to guinea pigs, 
a sustained release of the encapsulated drugs was observed for 3-5 days, while the free 
drugs were only present in plasma until 24 h, approximately. Moreover, as depicted in 
Figure 2, the administration of microcapsule formulations provided the detection of 
drugs in several organs (lungs, liver, spleen, intestine) up to 9 days, while the oral 
delivery of free drugs only resulted in detectable levels up to 48 h in liver and spleen. 
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Importantly, the microencapsulation approach permitted a 9-fold increase in 
bioavailability as compared with free drugs. A proof-of-concept study was performed 
using a tuberculosis animal model, demonstrating the elimination of bacilli in lungs and 
spleen after eight weeks of therapy comprising of a weekly oral administration. The 
same treatment duration was used for free drugs and similar results were observed, but a 
daily administration was required (Ain et al., 2003). The same group altered this 
formulation by including chitosan, in order to further improve bioavailability by 
retarding particle erosion and, thus, enabling the reduction of dosing frequency. The 
administration of a single oral dose of these new microparticles (70 µm) resulted in 
detectable plasma drug levels for 7 days (Figure 3), increasing the bioavailability in 
comparison with the formulation without chitosan (above). As compared with the 
results provided by simple alginate microspheres, which led to a 9-fold enhancement of 
bioavailability, these alginate-chitosan microspheres reached up to 19-fold 
bioavailability increase. Consequently, as compared with free drugs, a 15- and 13-fold 
increase in half-life and mean residence time, were observed. In addition, an interesting 
study provided a comparison between the in vivo administration of therapeutic and half-
therapeutic doses of the referred drugs to an animal model of the disease (guinea pigs). 
Oral administration of free drugs demanded 46 doses to eliminate the bacilli, while the 
same effect was observed with only 5 doses of microencapsulated drugs at therapeutic 
concentration or 7 doses at half-therapeutic concentration, administered every 10 days 
(Pandey and Khuller, 2004). The alginate and alginate-chitosan microspheres, were 
observed to provide a sustained drug release in intestinal medium (up to 20 days), which 
is in the basis of the prolonged detection of drugs in plasma for several days. For the 
formulation containing only alginate, this observation is rather unexpected, because 
alginate is a loose hydrogel network that degrades at the neutral pH characteristic of the 
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intestinal area (George and Abraham, 2006). As the encapsulated drugs have low 
molecular weight, and considering that the microspheres were not cross-linked, the 
observed release profile is even more surprising, but it probably relates to the proper 
alginate composition. It is known that drug release from alginate matrices is strongly 
affected by the matrix structure (Murata et al., 2007, d'Ayala et al., 2008). In this 
context, alginates with high guluronic content provide stiffer gels that maintain their 
integrity for long periods of time and exhibit restrict solute transport (d'Ayala et al., 
2008). Together with the mucoadhesive properties of the polymer, this has been the 
basis for the observation of the long lasting plasma drug levels. Concerning the 
formulation containing chitosan, the presence of this polycation was proposed to control 
microspheres porosity, enhancing the sustained release effect. The increased 
bioavailability observed upon incorporation of chitosan might be justified by the strong 
mucoadhesive properties of the polymer, as well as by its reported ability to transiently 
open tight junctions (Lehr et al., 1992, Braz et al., 2011). The demonstration of the 
possibility to control the delivery of drugs, achieving sustained plasma levels for several 
days is in fact a great step forward towards therapeutic advancements that might 
improve therapeutic efficiency. In this sense, higher bioavailability allows lower 
frequency of administration and, in the case of the formulation containing chitosan, 
even lower dose.  
There is also a work describing the use of gelatin/carboxymethylcellulose to prepare 
microparticles aimed at delivering isoniazid. Microparticles were produced by 
emulsification in presence of Tween 80
®
 and, although the authors do not refer to it 
directly, microparticle development was aimed at oral administration, because the 
smallest size observed for the systems is around 150-200 µm. Glutaraldehyde was used 
as cross-linker, evidencing the ability to modulate water uptake and drug release. Two 
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different degrees of cross-linking were tested, with the highest (17.5 mmol 
glutaraldehyde/g of polymer) resulting in 70% drug release in 48 h, in contrast with the 
lowest (4.375 mmol/g of polymer), which provided 90% of release at 24 h (Devi and 
Maji, 2009). Unfortunately, no data on the therapeutic efficacy of this system are 
available and, without a doubt, one of the major drawbacks of the developed system is 
the need to involve glutaraldehyde as cross-linker. 
As stated in the introduction, lung tuberculosis is the main manifestation of the disease 
and, therefore, the direct administration of anti-tubercular drugs to the lung, where the 
macrophages hosting the mycobacterium reside, appears as a logical and potentially 
promising approach. To address this possibility, ofloxacin-loaded hyaluronic acid 
microparticles (2-5 µm) were prepared by spray-drying and administered intratracheally 
to rats. The systemic bioavailability provided by microencapsulated ofloxacin, as 
compared to control intravenous and oral administration of drug solution in the same 
dose, was less than 50%, indicating a lower efficiency in the treatment of extra-
pulmonary tuberculosis. However, the concentration of the drug in the lung was 10-
times higher following direct delivery to the lung, demonstrating the great potential of 
the formulation in the therapy of lung tuberculosis. This effect was also much more 
pronounced for ofloxacin-loaded hyaluronic acid microparticles as compared to the 
unformulated powder of the drug (Hwang et al., 2008), evidencing a positive effect of 
the hyaluronic acid that is justified by its mucoadhesive character (Grabovac et al., 
2005). Encapsulation in presence of the polymer was also reported to enhance the in 
vitro uptake of ofloxacin by macrophages (cell line RAW 264.7), as compared to 
control ofloxacin microparticles spray-dried in the absence of polymer (Hwang et al., 
2008). Apart from the recognition of hyaluronan evidenced by CD44 receptors of 
macrophages, as the authors mentioned, this effect might be additionally attributed to a 
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specific recognition by lectin-type receptors that are also present, which recognise the 
N-acetylglucosamine residues (Taylor et al., 2005) comprising the structure of 
hyaluronic acid. 
Among all the described formulations of polymeric microparticles, only those 
composed by alginate were tested in animal models of the disease. Alginate-based 
microparticles demonstrated, thus, to be therapeutically effective when administered 
through the oral route. However, the formulation designed for direct lung delivery of 
ofloxacin might have potential in the treatment of lung tuberculosis, as demonstrated by 
the high lung drug levels that were reported. Nevertheless, with the exception of the 
works with alginate, the major flaw that is identified in formulation design relies in the 
use of a single drug. As pointed out in the introduction, the current approach of 
tuberculosis therapy always includes multiple drug administration, as single therapy is 
absolutely contra-indicated due to resistance issues. 
 
Polyalcohol microparticles 
Among the polyalcohols, only mannitol has been reported for an application in 
tuberculosis therapy. Mannitol (Figure 1) is a sugar alcohol that has been frequently 
used in particle formulation as matrix-forming material. In our group it was used several 
times as matrix material in microparticles designed for lung administration, as it 
provides good flow properties (Grenha et al., 2005, Grenha et al., 2008, Al-Qadi et al., 
2011). 
In the only work reporting its application, mannitol was used as matrix-forming material 
for the production of microparticles (3-4 µm) aimed at direct lung administration and 
rifampicin was used as anti-tubercular drug. The aerosolisation pattern of rifampicin 
was improved when microencapsulated with mannitol. However, intratracheal 
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administration in vivo to rats demonstrated that drug elimination is very rapid (only 4% 
of the drug remained in the lung after 1 h) (Mizoe et al., 2008), indicating an efficacy 
below the desired level to attain a therapeutic effect. This result was rather predictable, 
as mannitol is very soluble in aqueous medium and even in the presence of a small 
quantity of medium, as that existing in the alveolar zone, rapid dissolution of the 
microparticle matrix is expected, releasing the drug and enabling its rapid elimination. 
In this sense, as previously commented regarding some of the described works, the 
application of a mucoadhesive polymer as component of the microparticle matrix would 
be adequate to provide a more prolonged retention.  
 
Polymeric nanoparticles 
Works dedicated to the design of nanoparticulate carriers in the ambit of tuberculosis 
therapy almost double those of microparticles, as easily observed by consulting a 
database like ISI Web of Knowledge. This marked difference becomes even more 
relevant if considering that microencapsulation techniques have been available for a 
much longer time, as compared with technologies for nanoparticle production. The 
major reason for this difference is the fact that nanotechnologies have revealed a huge 
potential owing to their small dimensions, including the capacity for cell internalisation 
and to permeate epithelial barriers, as well as to improve encapsulation efficiency, 
compared with microparticles (Ranjita et al., 2011, Pandey and Ahmad, 2011, Ahmad et 
al., 2006a). The mentioned difference in the number of works between nano and 
microparticles is not observed when natural materials are used, instead being 
approximately similar. Nevertheless, the list of natural polymers used in the formulation 
of nanoparticles proposed as vehicles in tuberculosis therapy is even narrower as 
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compared to that of microparticles, comprising only alginate, chitosan, gelatin and 
dextran sulfate (chemical structures of materials depicted in Figure 1).  
Curiously, the first report on natural nanoparticle carriers addressing tuberculosis 
therapy was devoted to inhalation. Although the authors refer to the system merely as 
alginate nanoparticles, which were formed by gelification with calcium ions, these were 
subsequently coated with chitosan by electrostatic interaction. Isoniazid, pyrazinamide 
and rifampicin were encapsulated in the nanoparticles (235 nm) at a drug/polymer ratio 
of 7.5/1 and administered by nebulisation to guinea pigs infected with Mycobacterium 
tuberculosis. Aerodynamic studies revealed that 80% of the nebulised particles were in 
the respirable range, ensuring alveolar deposition. Very interesting results were obtained 
in vivo (Table 4), so that only 3 doses of nanoparticles in a total of 45 days resulted in 
undetectable mycobacteria in lung and spleen homogenates; the same observation 
registered upon 45 daily doses of the free drugs by the oral route. This tremendous 
reduction in dosing frequency was possible owing to the detection of drug levels in 
plasma for up to 14 days after nanoparticle administration, as compared to only 1 day 
upon administration of free drugs. Additionally, enhanced tissue bioavailability was 
also reported in several organs (lungs, liver spleen), as encapsulated drugs provided 
detectable levels up to 15 days (Ahmad et al., 2005b). In spite of the promising results, 
a broad characterisation of the nanoparticles is missing (morphological studies, in vitro 
release, etc.), limiting the discussion of results. Unfortunately, this research line was not 
continued until now, as no more recent data are available.  
In turn, a decision was apparently made to proceed with the application of the 
formulation in oral delivery. One of the reasons pointed as the basis of this decision is 
the fact that nanoparticle uptake by intestinal cells has been reported several times, 
either by the M-cells located in the Peyer’s patches (Borges et al., 2006, Pinto Reis et 
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al., 2006) or by the enterocytes, benefiting from transcellular and paracellular transport 
(Cai et al., 2010, Pinto Reis et al., 2006). A first study revealed that, after oral delivery 
to mice of alginate nanoparticles containing the three drugs mentioned above plus 
etambutol, plasma drug levels were detected during 7-13 days. As happened before 
upon inhalation, tissue drug levels were detected up to 15 days. In contrast, the 
administration of free drugs led to plasma and tissue elimination within 24 h (Ahmad et 
al., 2006c). A second work provided the in vivo proof-of-concept of the formulation for 
oral administration, demonstrating that 3 oral doses of encapsulated drugs administered 
fortnightly to Mycobacterium tuberculosis-infected mice, resulted in complete bacterial 
clearance, as was observed upon administration of 45 daily doses of free drugs (Ahmad 
et al., 2006a). A later approach has associated econazole to the four anti-tubercular 
drugs used before (Ahmad et al., 2007), benefiting from its demonstrated potent anti-
tubercular activity and synergism with some anti-tubercular drugs (Ahmad et al., 
2005a). In fact, econazole has proven to have similar chemotherapeutic potential as 
compared with rifampicin (Ahmad et al., 2006d, Ahmad et al., 2006b). In the referred 
work, it was observed that Mycobacterium tuberculosis-infected mice had undetectable 
bacterial levels after 30 days of treatment with alginate nanoparticles encapsulating 
econazole and three of the usual anti-tubercular drugs (fortnight administration, except 
for econazole that demands a weekly administration). The same result was obtained 
with the daily administration of the free drugs (twice daily for econazole). Econazole 
was demonstrated to substitute rifampicin or isoniazid without compromising the final 
therapeutic outcome (Ahmad et al., 2007).  
Three other works reported the use of natural nanoparticle carriers for anti-tubercular 
drugs, both sharing the major limitation of encapsulating and delivering a single drug. 
In one case, chitosan-coated complexes of streptomycin and dextran sulfate (500 nm) 
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are administered daily through the oral route to Mycobacterium tuberculosis-infected 
mice for a period of 3 weeks. Bacterial levels decreased by about 15% as compared to 
untreated animals and a similar result was obtained upon the same schedule of 
subcutaneous administration of streptomycin solution (Lu et al., 2009). The efficacy of 
the formulation is substantially lower than that observed for alginate formulations 
presented before and, unfortunately, controls such as the oral administration of free 
drug, for instance, were not reported. Gelatin nanocarriers prepared by desolvation (264 
nm) were also proposed, this time for the intravenous administration of rifampicin to 
mice. Although the administration of nanoparticles was more efficacious than free 
drugs, 10 doses administered every 3 days only reduced bacterial levels in lungs and 
spleen by about 50%, without completely eliminating the bacteria (Saraogi et al., 2010). 
More recently, these nanoparticles were conjugated with mannose and loaded with 
isoniazid, and then administered intravenously to mice, as a means of providing a direct 
targeting of alveolar macrophages (Saraogi et al., 2011), taking benefit from the 
presence of mannose receptors in macrophages surface (Ahsan et al., 2002, Geiser, 
2010). Lung targeting was achieved and a 3-fold higher reduction of mycobacteria was 
observed upon the administration of mannosylated nanoparticles, as compared to free 
drug. Although to a lower extent, non-mannolsylated nanoparticles also improved 
bacterial elimination as compared to free drugs, registering a 2-fold higher reduction. 
This is a clear indication of a more effective internalization by macrophages of the 
nanoparticles bearing surface residues of mannose, as also demonstrated in an in vitro 
assay with a macrophage cell line (J774) (Saraogi et al., 2011).  
As observed for the microparticulate systems, alginate-based formulations were the 
most successful in eliminating bacteria. Interestingly, the presented set of works 
demonstrated that 3 doses of drug loaded chitosan-coated alginate nanoparticles, either 
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administered orally or by inhalation with intervals of 15 days, are effective in 
eliminating mycobacteria from the affected tissues. Importantly, therapy duration can be 
further reduced by substituting rifampicin or isoniazid by econazole, providing bacterial 
elimination with only 2 fortnight doses. 
 
Solid lipid nanoparticles 
Solid lipid nanoparticles differ from polymeric nanoparticles in their composition, 
which is based on lipids. This lipidic content endows the nanoparticles with 
biocompatibility and biodegradability. In addition, as compared to liposomes, their 
production is easily scalable and they offer increased drug protection, as there is limited 
access of water to the inner lipidic core (Martins et al., 2007, Attama, 2011). These 
nanoparticles were previously used successfully to improve the bioavailability of 
distinct drugs, such as idarubicin (Zara et al., 2002), tobramycin (Cavalli et al., 2003) 
and insulin (Fonte et al., 2012), amongst others. 
In the context of anti-tubercular therapy, solid lipid nanoparticles based on stearic acid 
(Figure 1) and prepared by emulsion solvent diffusion were loaded with rifampicin, 
isoniazid and pyrazinamide, and administered by both the oral (Pandey et al., 2005) and 
the pulmonary route (Pandey and Khuller, 2005b) to Mycobacterium tuberculosis-
infected mice and guinea pigs, respectively. After oral administration, therapeutic drug 
levels were detected in plasma for 8 days and in tissues (lung, spleen, liver) for 10 days. 
Five oral doses administered each 10 days led to undetectable levels of bacteria, 
whereas equivalent therapeutic result was obtained after 46 daily doses of free drugs 
(Pandey et al., 2005). Inhalable therapy (nebulisation) led to shorter availability times (5 
days in plasma and 7 days in tissues) but was also therapeutically effective, providing 
elimination of the bacilli after 7 weekly doses of the formulation (Pandey and Khuller, 
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2005b). Although the results seem interesting, a thorough characterisation of the 
nanoparticles is not available. Actually, important parameters such as the morphological 
and physicochemical properties, namely size and zeta potential, which are known to 
strongly affect the performance of nanoparticulate carriers, are missing, compromising 
the interpretation of results. As applied before to polymeric nanoparticles, 
mannosylation was also used as a strategy to improve macrophage targeting of solid 
lipid nanoparticles. Mannosylated solid lipid nanoparticles loaded with rifabutin (390 
nm) revealed a 6-times increase in particle uptake (in vitro, macrophage cell line J774) 
and more prolonged drug retention in plasma (96 h as compared to 72 h provided by 
non-mannosylated particles and 48 h of free drug) and tissues after intravenous 
administration of one dose (Nimje et al., 2009). 
Solid lipid nanoparticles have recently emerged as promising technology, particularly 
for the delivery of hydrophobic drugs, as with for many anti-tubercular drugs. Owing to 
the generally regarded as safe status of lipids and the previously mentioned advantages 
in comparison with liposomes, there are some indications on their effectiveness as drug 
carriers. Nevertheless, in the particular case of anti-tubercular therapy, an additional 
number of studies would be needed to state their usefulness. 
 
Conclusions and perspectives 
As stated through the review, a great number of works devoted to tuberculosis has been 
focusing on the design of new therapeutic alternatives for this pertinent disease, 
particularly addressing the limitation of low patient compliance caused by prolonged 
therapies and associated side-effects. The defined strategy focuses on encapsulation 
procedures that modify drug pharmacokinetics and, in some cases, further approach the 
use of unconventional routes of administration. Encapsulation automatically provides 
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the drugs with prolonged half-life, because drug delivery systems take longer to be 
eliminated as compared with free drug molecules, especially if the used polymers are 
hydrophilic (Pandey and Ahmad, 2011). In addition, with the selection of an adequate 
carrier composition, sustained drug release can be attained, leading to a reduction in 
dosing frequency and to decreased side-effects. In fact, the outstanding effect of 
achieving controlled release is the tremendous improvement in therapeutic schedules, 
replacing the usual 46 daily oral doses by a much reduced number of administrations. 
As demonstrated in some of the described studies, a total of 2 or 3 administrations 
spaced by two weeks, might be enough for bacterial elimination, which would represent 
an enormous improvement on therapeutic frequency. In some cases, however, the works 
propose intravenous administration. Considering that this encompasses painful 
procedures, higher infection risks and requires skilled personal, it is not the ideal route 
on admitting a marketing approach. Additionally, taking into account that developing 
countries would be the main beneficiary of these new therapeutic lines, parenteral 
administration should not be pondered, as it raises the problem of demanding sterilised 
material that in most cases is not possible to provide.  
The oral and pulmonary routes were proposed in the majority of works, addressing this 
limitation, although inhalation is focused in a lower number of reports, comparatively. 
Bearing in mind the previously mentioned prevalence of lung tuberculosis, systemic 
absorption of drugs released from orally administered drug delivery systems is 
demanded and their delivery to the lung expected. In parallel, although theoretically 
drug delivery systems could be taken up by intestinal M-cells and delivered to the lungs 
through the lymphatic circulation (Florence, 1997, Hans and Lowman, 2002), several 
works have demonstrated the absence of efficacy of this strategy (Azarmi et al., 2008). 
In the development of tuberculosis therapy it is important to consider that 
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Mycobacterium tuberculosis is an intracellular parasite, especially in the chronic phase 
of the disease. Therefore, whatever the route of administration, once in the lung, 
intracellular internalisation of drugs is necessary (Barrow, 2004).  
In this context, delivering encapsulated anti-tubercular drugs directly to the lung might 
be a very useful approach and has demonstrated in several works to enhance local (lung 
tissue) bioavailability, serving as targeted anti-tubercular drug delivery. This approach 
optimises drug therapeutic index by increasing drug concentration ratio of diseased 
tissue to normal tissue (Saraogi et al., 2010), improving chemotherapeutic efficacy and 
reducing dose frequency. In addition, by avoiding high plasma drug levels, usual toxic 
effects are dramatically reduced. Nevertheless, considering the intracellular localisation 
of the bacteria, an increase in tissue levels is only relevant if leading to an intracellular 
accumulation of the drugs and, therefore, care must be taken on the interpretation of 
results. An additional advantage of inhaled carrier-based therapies relies on the 
activation of infected macrophages as a consequence of the uptake of particulates, 
resulting in improved bactericidal activity (Mosser, 2003, Lewis and McGee, 1992). 
Notwithstanding the promising inhalation approach, several important limitations have 
been noted, including limited access to poorly aerated areas of the lung, resistance 
derived from intracellular drug concentration and immunopathological reactions derived 
from macrophage activation (Yadav et al., 2011). 
Considering that the lung is the port of entrance of tuberculosis infecting agent and 
taking into account the mentioned prevalence of lung tuberculosis, the absence of a 
commercial inhalable therapy can be surprising. It seems logical to assume that 
formulating inhalable delivery systems is much more challenging than designing oral 
systems, but that is possibly only the easiest justification. Indeed, lung delivery is much 
less studied and its impact on general health is not really established, raising a strong 
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concern that both does not stimulates researchers and makes regulatory agencies to be 
very cautious regarding the approval of these therapies. 
As previously mentioned, no matter what the route of delivery, using drug delivery 
systems is a key factor in meeting the mandatory requirements of decreasing dosing 
frequency and side-effects. Nano and microparticles have taken the forefront of this 
challenge and polyesters such as PLA and PLGA lead the list of materials described to 
compose their matrices. The reason for this fact is easily attributed to their reported 
biocompatibility and to the variable methods described to produce the carriers. 
However, important limitations of these synthetic materials have also been identified, 
such as low encapsulation efficiencies and difficulties to eliminate organic solvents 
involved in carrier production methods. The interest is now turning to the application of 
natural materials, which are produced with much more rapid and mild methods, have a 
lower cost and evidence similar biocompatibility profile. In addition, if adequately 
selected, they can permit a direct targeting of macrophages, by specific recognition 
mediated by alveolar surface receptors. In this context, macrophages express various 
surface receptors, including Fc, mannosyl, lectin, and galactosyl (Ahsan et al., 2002, 
Geiser, 2010), and this strategy would present the outstanding advantage of delivering 
therapeutically effective drug concentrations to the primary site of infection (Smola et 
al., 2008). 
In comparison with microparticles, nanoparticles usually provide higher drug loading 
(Ahmad et al., 2011). However, the selection of one system or the other might be 
dependent on the designated route of administration. When oral delivery is intended, 
nanoparticles might be able to provide not only a more effective controlled release of 
drugs, but also the possibility of systemic transport of the carriers. Pulmonary delivery 
is also possible for both nanoparticles and microparticles, but while micron-sized 
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carriers can be tuned to display the adequate aerodynamic properties to achieve the 
alveolar zone, nanocarriers require additional processing such as subsequent 
microencapsulation to provide a dry powder formulation or the use of nebulisation to 
afford the adequate dimensions. On the contrary, if macrophage targeting is aimed 
through inhalation, it was suggested that microparticles of 1-3 µm have maximal uptake 
(Ahsan et al., 2002, Misra et al., 2011), while that of submicron particles was rather 
sporadic and unintentional (Geiser, 2010). In this manner, if by one side nanomedicines 
seem to be the most adequate and efficacious solutions for improving TB therapy in oral 
delivery, microparticles are possibly the most promising for the treatment of lung 
tuberculosis by inhalation. In the latter approach, carriers displaying surface molecules 
specifically recognised by macrophage surface receptors (i.e. mannose) have improved 
targeting efficacy. Organic synthesis is usually applied to conjugate the targeting 
ligands to the polymers, but the same purpose might be achieved with the selection of 
proper natural materials. In this context, it was demonstrated in a previous work that 
chitosan microparticles were captured by alveolar macrophages after intra-tracheal 
administration to rats (Al-Qadi et al., 2012). Although the microparticle-cell interaction 
was not specifically studied, maybe recognition of N-acetylglucosamine units took 
place, in addition to the natural tendency of macrophages for particle internalisation. 
In the whole approach of developing alternative strategies that permit an increase of 
patient compliance, some important details are, however, still to be improved. In many 
cases, works report single drug therapy, which is not adequate because of drug 
resistance. Instead, multidrug therapeutic approaches are mandatory for research aiming 
at real implementation. On the other side, it is very important to realise that even the 
more realistic assays performed in infected animals, do not necessarily describe the 
outcome to be obtained in humans. As a matter of fact, a much important parameter 
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such as macrophage turnover time is absolutely variable within species, being reported 
as 21-28 days in mouse and 81 days in humans (Geiser, 2010). Moreover, it is also 
important to consider the general concern lying around the administration of particulate 
matter to the lung (Misra et al., 2011), as little information is available on the subject 
reporting human application. 
It is a fact that, so far, only a limited number of formulations undertook in vivo testing 
regarding therapeutic effectiveness. Nevertheless, with the important outcomes 
described through this review, it seems realistic to suppose that future anti-tubercular 
therapy will follow the basis of the proposed strategies, using carrier-based approaches. 
Natural polymers seem to have a word in this context, but more studies are obviously 
needed to explore the whole potential of these materials, namely in what concerns the 
use of a wider variety of polymers. 
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Figure legends 
Figure 1. Chemical structures of natural materials used in the production of 
multiparticulate carriers proposed for tuberculosis therapy. 
Figure 2. Tissue levels of alginate-encapsulated isoniazid, rifampicin and pyrazinamide 
(in combination) when administered orally to guinea pigs. Values are means ± S.D. of 
7–8 animals. Reproduced from Ain et al. (2003) with permission. 
Figure 3. The profile of anti-tuberculous drugs in plasma following the single oral 
administration of ATD-loaded alginate–chitosan microspheres and free drugs (in 
combination) to guinea pigs. (a) Plasma rifampicin; (b) plasma isoniazid; and (c) plasma 
pyrazinamide. Values are means ± S.D. of eight animals for alginate–chitosan 
microspheres and six animals for free drugs. Reproduced from Pandey and Khuller 
(2004) with permission. 
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Table 1. Advantages and limitations of natural polymers for the production of drug 
delivery carriers. 
Advantages Limitations 
Flexibility Inter-batch variability 
Low cost Limited availability (if widely used) 
Ease of extraction Complex and varied composition 
Hydrophilicity Difficult to process 
Biocompatibility, biodegradability Low mechanic properties 
  
Page 28 of 34
URL: http://mc.manuscriptcentral.com/tmnc  Email: microencapsulation@hotmail.co.uk
Journal of Microencapsulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
         29 
Table 2. Description of studies performed with natural micro- and nanocarriers in the ambit of anti-tubercular drug delivery. 
Materials Associated 
molecules 
Administration 
route 
Drug delivery 
system 
Major findings Ref. 
Gelatin 
Carboxymethyl 
cellulose 
Isoniazid Not applicable Microparticles Glutaraldehyde acted as cross-linker, modulating drug release (17.5 
mmol glutaraldehyde/g of polymer provided 70% release in 48h) 
(Devi and Maji, 
2009)  
Alginate Isoniazid, 
rifampicin, 
pyrazinamide 
Oral Microparticles Encapsulation provided plasma drug levels for 3 to 5 days, while free 
drugs were eliminated within 24h, after single dose administration to 
guinea pigs. Encapsulated drugs were detected in tissue up to 9 days, 
while free drugs only for 48h 
(Ain et al., 2003)  
Alginate 
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide 
Oral Microparticles Encapsulated drugs provided 15-fold and 13-fold increase in drug half-
life and mean residence time, respectively 
Pandey and 
Khuller, 2004)  
Hyaluronic acid Ofloxacin Intratracheal Microparticles Microencapsulated ofloxacin resulted in less than 50% bioavailability as 
compared with control intravenous and oral administration of drug 
solution to rats. Lung drug concentration was 10-times higher after direct 
lung delivery 
(Hwang et al., 
2008)  
Mannitol Rifampicin Intratracheal Microparticles Drug elimination is very rapid, with only 4% of drug remaining in the 
lung 1h after administration 
(Mizoe et al., 
2008)  
Alginate 
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide 
Pulmonary Nanoparticles Nebulised nanoparticles display a respirable fraction of 80%. Drug levels 
detected in plasma up to 14 days after nanoparticle administration, while 
only 24h after free drug administration. Encapsulation provided 
enhanced tissue bioavailability 
(Ahmad et al., 
2005b)  
Alginate  
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide,
etambutol 
Oral Nanoparticles Administration of nanoencapsulated drugs provided plasma drug levels 
for 7-13 days and tissue levels for 15 days. Free drugs were eliminated 
within 24h 
(Ahmad et al., 
2006c) 
Stearic acid Isoniazid, 
rifampicin, 
pyrazinamide 
Oral Solid lipid 
nanoparticles 
Therapeutic drug levels detected in plasma for 8 days and in tissue for 10 
days 
(Pandey et al., 
2005) 
Stearic acid Isoniazid, 
rifampicin, 
pyrazinamide 
Pulmonary Solid lipid particles Therapeutic drug levels detected in plasma for 5 days and in tissue for 7 
days 
(Pandey and 
Khuller, 2005b) 
Stearic acid 
Mannose 
Rifabutin Intravenous Solid lipid 
nanoparticles 
Mannosylation increases macrophage particle uptake by 6-fold and 
provides prolonged drug plasma levels (96h as compared to 72h of non-
mannosylated nanoparticles and 48h for free drug) 
(Nimje et al., 
2009) 
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Table 3. Description of in vivo studies performed with natural micro- and nanocarriers in animal models of tuberculosis. 
Materials Associated 
molecules 
Drug delivery 
system 
Animal/Route of 
administration 
Major findings Ref. 
Alginate Isoniazid, 
rifampicin, 
pyrazinamide 
Microparticles Guinea pig 
Oral 
Once-a-week administration of encapsulated drugs for 8 weeks eliminated 
bacilli from lungs and spleen. Once-a-day administration of free drugs for 
the same period achieved the same result. 
(Ain et al., 2003)  
Alginate 
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide 
Microparticles Guinea pigs 
Oral 
Five doses of microencapsulated drugs at therapeutic concentration or 7 
doses at half-therapeutic concentration, administered with 10-day interval 
eliminated bacilli. Same effect observed for 46 daily doses of free drugs. 
(Pandey and 
Khuller, 2004)  
Alginate 
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide 
Nanoparticles Guinea pigs 
Pulmonary 
Bacilli elimination was achieved with 3doses of nebulised nanoparticles in a 
total of 45 days. Similar effect obtained upon 45 daily doses of free oral 
drugs 
(Ahmad et al., 
2005b)  
Alginate  
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide,
etambutol 
Nanoparticles Mice 
Oral 
Nanoencapsulated drugs administered fortnightly permitted bacterial 
elimination after 3doses, while free drugs needed 45 daily doses 
(Ahmad et al., 
2006a) 
Alginate  
Chitosan 
Isoniazid, 
rifampicin, 
pyrazinamide,
etambutol, 
econazole 
Nanoparticles Mice 
Oral 
Fortnight administration of any 3 of the nanoencapsulated drugs selected 
from isoniazid, rifampicin, pyrazinamide and etambutol plus weekly 
administration of nanoencapsulated econazole eliminated bacteria after 30 
days. 
(Ahmad et al., 
2007) 
Chitosan  
Dextran sulfate 
Streptomycin Nanoparticles Mice 
Oral 
Daily administration of chitosan-coated streptomycin/dextran sulfate 
complexes for 3 weeks decreases 15% bacterial levels; the same result 
obtained for similar schedule of subcutaneous administration of free drug 
(Lu et al., 2009) 
Gelatin Rifampicin Nanoparticles Mice 
Intravenous 
Ten doses of encapsulated drug administered every 3 days reduced 50% 
bacterial levels in lung and spleen 
(Saraogi et al., 
2010) 
Gelatin 
Mannose 
Isoniazid Nanoparticles Mice 
Intravenous 
Drug-loaded mannosylated-nanoparticles achieved 3-fold higher reduction 
of bacterial levels as compared to free drug 
(Saraogi et al., 
2011) 
Stearic acid Isoniazid, 
rifampicin, 
pyrazinamide 
Solid lipid 
nanoparticles 
Mice 
Oral 
Five oral doses administered each 10 days resulted in bacterial elimination. 
Similar results observed upon 46 daily doses of free drugs 
(Pandey et al., 
2005) 
Stearic acid Isoniazid, 
rifampicin, 
pyrazinamide 
Solid lipid 
nanoparticles 
Guinea pigs 
Pulmonary 
Seven weekly doses of encapsulated drug provided bacilli elimination (Pandey and 
Khuller, 2005b) 
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Table 4. Chemotherapeutic efficacy of aerosolised alginate nanoparticle encapsulating 
antitubercular drugs against experimental tuberculosis in guinea pigs. Reproduced from 
Ahmad et al. (2005b) with permission. 
Group log10 CFUs
a
 
Lung (right caudal 
lobe) 
Spleen 
(whole organ) 
Untreated controls 5.8 ± 0.1 5.9 ± 0.1 
Empty alginate nanoparticles every 15 days, 
aerossol (3 doses) 
5.8 ± 0.3
*
 5.9 ± 0.1 
Drug-loaded alginate nanoparticles every 15 
days, aerosol (3 doses) 
<1.0
b
 <1.0
b
 
Free drugs daily, orally (45 doses) <1.0
b
 <1.0
b
 
a Results are based on visible growth of Mycobacterium tuberculosis on Middlebrook 7H10 agar on day 21 post 
inoculation. Results are mean±S.D (N= 5–6); b Value <1.0 indicates no detectable CFUs following the inoculation of 
50 µL of neat and 1:10 diluted tissue homogenates; *P > 0.05 according to ANOVA; CFUs: colony forming units. 
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Figure 1. Chemical structures of natural materials used in the production of multiparticulate carriers 
proposed for tuberculosis therapy.  
 
 
Page 32 of 34
URL: http://mc.manuscriptcentral.com/tmnc  Email: microencapsulation@hotmail.co.uk
Journal of Microencapsulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Figure 2. Tissue levels of alginate-encapsulated isoniazid, rifampicin and pyrazinamide (in combination) 
when administered orally to guinea pigs. Values are means ± S.D. of 7–8 animals. Reproduced from Ain et 
al. (2003) with permission.  
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Figure 3. The profile of anti-tuberculous drugs in plasma following the single oral administration of ATD-
loaded alginate–chitosan microspheres and free drugs (in combination) to guinea pigs. (a) Plasma 
rifampicin; (b) plasma isoniazid; and (c) plasma pyrazinamide. Values are means ± S.D. of eight animals for 
alginate–chitosan microspheres and six animals for free drugs. Reproduced from Pandey and Khuller (2004) 
with permission.  
143x218mm (72 x 72 DPI)  
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